Orphazyme A/S Accounts Payable

The latest accounts payable for ORPH is $700K as of June 2026. That compares with $790K in the prior-year period — down 11.0% year over year. Investors often review this figure alongside Orphazyme A/S's historical trend and sector peers before judging valuation or financial health.

Over the past year, ORPH's accounts payable moved from $790K to $700K — a 11.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Orphazyme A/S's operating scale or balance-sheet position.

A accounts payable figure of $700K for ORPH is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting ORPH's accounts payable ($700K), review year-over-year change from $790K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Orphazyme A/S's accounts payable against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.